In preclinical studies, the combination of ICIs, such as anti-PD-1/PD-L1, with EGFR blockers has been found to improve the efficacy of ICIs in NSCLC and CRC [172,173,174]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.